PDCD1 and metastatic neoplasm: In this regard, the ICIs nivolumab and pembrolizumab, which specifically bind to immune checkpoint receptor programmed cell death protein 1 (PD-1), have been approved for patients with recurrent or metastatic disease previously treated with platinum chemotherapy, conferring a survival benefit in 20–30% of patients [16,18,19].